- Topic
5k Popularity
34k Popularity
16k Popularity
9k Popularity
2k Popularity
922 Popularity
44 Popularity
139k Popularity
2k Popularity
1743k Popularity
- Pin
- Welcome Kevin_Lee to the Gate Square! 🎉
Looking forward to more great crypto insights from him.
Check out and engage with Kevin_Lee’s latest post!
👉 Post: https://www.gate.com/post/status/11758920
👉 Profile: https://www.gate.com/profile/Kevin%20Lee
Let’s give Kevin_Lee a warm welcome! 👏👏👏
- 🎯 LOT Newcomer Limited-Time Airdrop is Live!
Individual users can earn up to 1,000 LOT — share from a total prize pool of 1,000,000 LOT!
🏃 Join now: https://www.gate.com/campaigns/1294
Complete deposit and trading tasks to receive random LOT airdrops. Exclusive Alpha trading task await!🎯 LOT Newcomer Limited-Time Airdrop is Live!
Individual users can earn up to 1,000 LOT — share from a total prize pool of 1,000,000 LOT!
🏃 Join now: https://www.gate.com/campaigns/1294
Complete deposit and trading tasks to receive random LOT airdrops. Exclusive Alpha trading task await!
- 🎯 How to Earn Content Mining Rewards on Gate Post?
1️⃣ Create a post on Gate Post
2️⃣ Get likes or comments from other users
3️⃣ If those users trade (spot or futures) shortly after engaging with your post...
💰 You earn up to 10% commission on their trading fees!
📢 Share ✍️ Engage 💬 Earn 💰
- 🚀 Gate Square Creator Spark Program is Live!
We're officially recruiting the first batch of creators on Gate Square! Whether you're a crypto KOL, project team, or media outlet, join now and enjoy:
💰 Over $10,000 in monthly posting rewards
📣 Exposure to millions of Gate users
📢 Featured promotion and official support
🔥 Don't miss this early-mover advantage — apply now 👉 https://www.gate.com/questionnaire/6819
📄 More info 👉 https://www.gate.com/announcements/article/45695 - 🎉 Gate Alpha Second Points Special Airdrop is coming!
Get Token Mystery Boxes based on your Alpha Points - No points will be deducted.
📸 Alpha Points Snapshot: June 24, 16:00 (UTC)
Multi-chain trading now supported — buy on-chain assets directly with USDT!
🔗 Full details: https://www.gate.com/announcements/article/45683
Innovent Biologics: Positive Results from Phase II Clinical Trial of Innovative Drug ICP-488
Jinshi data news on October 9th, Norcheng Jianhua announced in the evening that the company's innovative drug ICP-488 achieved positive clinical trial results in a phase II randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis. The results showed that patients treated with 6mg and 9mg (once daily) of ICP-488 had significant improvement in PASI75 at week 12 compared to patients receiving placebo. In addition, the proportion of patients receiving ICP-488 treatment who achieved PASI90, PASI100, and static Physician Global Assessment (sPGA) 0/1 (i.e., complete or near-complete clearance of skin lesions) was significantly higher than that in the placebo group.